ClinicalTrials.gg
CompletedNCT05153148Updated May 31, 2024Results posted

A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis

A Phase 2 interventional study of NDI-034858 and Placebo in Psoriatic Arthritis, sponsored by Takeda. Completed at 56 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-05-31.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
305
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 193 studies in Arthritis, Psoriatic with a site in United States — 29 open to participants now, 59 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.

Enrollment
69th of 158
305 · median 237
Started
2022
with 10 others
Phase 2
31 of 193
3 open now
Registered
140th of 193
by date

Among the 193 studies in Arthritis, Psoriatic with a site in United States, this one is the 69th largest by enrollment of the 158 interventional ones that give a count, is one of 11 that started in 2022, is one of 31 in phase 2, and was the 140th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

29 of the 193 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Arthritis, Psoriatic with a site in United States, or all of them as a file.
02

Study summary

This study is designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with active Psoriatic Arthritis (PsA).

Read the detailed description

This is a Phase 2b, Randomized, Multi-center, Double-Blind, Placebo-Controlled, Multiple Dose Study.

Randomization to one of the treatments with NDI-034858 Dose 1, 2, 3 or placebo once daily (QD) will be based on a 1:1:1:1 scheme.

The maximum study duration per participant is approximately 20 weeks, including up to 30 days for the screening period, a 12-week treatment period, and a 4-week safety follow-up period.

Efficacy will be assessed using the ACR20 composite measure (including tender and swollen joint count, patient assessment of PsA pain visual analog scale (VAS), patient global PsA assessment VAS, physician global PsA assessment, HAQ-DI, and hsCRP) as well as the additional components. Efficacy for psoriasis among participants who have ≥ 3% BSA) involvement on Day 1, will be measured using PASI, PGAs, and BSA.

Safety will be assessed by collecting AEs, recording vital signs, performing physical examinations, and evaluating clinical laboratory and ECGs results.

Blood samples will be collected to measure plasma concentrations of NDI-034858.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • Placebo-Controlled
  • Double-blind
  • Multiple-dose study
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has PsA on the basis of the Classification Criteria for Psoriatic Arthritis with peripheral symptoms at the screening visit.
  • Participant has a history of PsA symptoms for ≥ 6 months prior to the screening visit.
  • Participant has ≥ 3 tender joints and ≥ 3 swollen joints at screening and Day 1 visits.
  • Participant has at least one lesion of plaque psoriasis ≥ 2 cm in diameter, nail changes characteristic of psoriasis, or a documented history of plaque psoriasis.
  • Participant has active PsA despite previous standard doses of non-steroidal anti-inflammatory drug (NSAIDs) administered for ≥ 4 weeks, or traditional disease-modifying anti-rheumatic drug (DMARDs) (including methotrexate and sulfasalazine) administered for ≥ 3 months, or tumor necrosis factor inhibitor (TNFi) agents administered for ≥ 3 months, or participants are intolerant to NSAIDs or DMARDs or TNFi agents.
  • If participant is on concurrent PsA treatments, they must be on stable doses.
  • All female participants should followed the protocol defined method.

Exclusion criteria

Exclusion Criteria:

  • Participant has other disease(s) that might confound the evaluations of benefit of NDI-034858 therapy, including but not limited to rheumatoid arthritis (RA), axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, Lyme disease, or fibromyalgia.
  • Participant has a history of lack of response to any therapeutic agent targeting IL-12, IL17, and/or IL23 at approved doses after at least 12 weeks of therapy, and/or received one of these therapies within 6 months prior to baseline (Day 1).
  • Participant has a history of lack of response to > 1 therapeutic agent targeting tumor necrosis factor.
  • Participant has received infliximab, golimumab, adalimumab, or certolizumab pegol, or any biosimilar of these agents, within 8 weeks prior to baseline (Day 1).
  • Participant has received etanercept, or any biosimilar of etanercept, within 4 weeks prior to baseline (Day 1).
  • Participant has received rituximab or any immune-cell-depleting therapy within 6 months prior to baseline (Day 1).
  • Participant has received any marketed or biological agent, other than those specified in other inclusion/exclusion criteria, within 12 weeks or 5 half-lives prior to baseline (Day 1).
  • Participant is currently receiving a non-biological investigational product or device or has received one within 4 weeks prior to baseline (Day 1).
  • Participant has received apremilast or other non-biologic systemic treatment for PsA within 4 weeks prior to baseline (Day 1), other than methotrexate (MTX), sulfasalazine, , NSAIDs, or paracetamol/acetaminophen, which are allowed at stable doses as described in Inclusion Criterion 7. For participants not receiving MTX and sulfasalazine at screening, MTX and sulfasalazine are excluded within 4 weeks prior to baseline (Day 1). Participant has received leflunomide within 8 weeks of baseline (Day 1) if no elimination procedure was followed or adhere to an elimination procedure. For participants not receiving MTX and sulfasalazine at Screening, MTX and sulfasalazine are excluded within 4 weeks prior to baseline (Day 1).
  • Participant has received intraarticular injection (including corticosteroids), intramuscular steroids, intralesional steroids, or intravenous steroids within 4 weeks prior to baseline (Day 1). For participants not receiving MTX and sulfasalazine at screening, MTX and sulfasalazine are excluded within 4 weeks prior to baseline (Day 1). For participants not receiving MTX and sulfasalazine at screening, MTX and sulfasalazine are excluded within 4 weeks prior to baseline (Day 1).
  • Participant has received high potency opioid analgesics (eg, methadone, hydromorphone, or morphine) within 2 weeks prior to baseline (Day 1).
  • Participant has used any topical medication that could affect PsA or psoriasis (including corticosteroids, retinoids, vitamin D analogues (such as calcipotriol), JAK inhibitors, or tar) within 2 weeks prior to baseline (Day 1).
  • Participant has used any systemic treatment that could affect PsA or psoriasis (including oral retinoids, /immunomodulating medication, cyclosporine, oral JAK inhibitors, or apremilast) within 4 weeks prior to baseline (Day 1).
  • Participant has received any ultraviolet (UV)-B phototherapy (including tanning beds) or excimer laser within 4 weeks prior to baseline (Day 1).
  • Participant has had psoralen and UV A (PUVA) treatment within 4 weeks prior to baseline (Day 1).
  • Participant has received Chinese traditional medicine within 4 weeks prior to baseline (Day 1)
  • Participant has received any , including for COVID-19, within 4 weeks prior to baseline (Day 1) or plans to receive a live-attenuated vaccine during the study and up to 4 weeks or 5 half-lives of the study drug, whichever is longer, after the last study drug administration.
  • Participant is currently being treated with strong or moderate cytochrome P450 3A () inhibitors, such as itraconazole or has received moderate or strong CYP3A4 inhibitors within 4 weeks prior to baseline (Day 1).
  • Participant has consumed grapefruit or grapefruit juice within 1 week prior to baseline (Day 1).
  • Participant has used tanning booths within 4 weeks prior to baseline (Day 1), has had excessive sun exposure, or is not willing to minimize natural and artificial sunlight exposure during the study.
  • Participant is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
  • Participant has evidence of erythrodermic, pustular, predominantly guttate psoriasis, or drug-induced psoriasis.
  • Participant has any medical condition, evidence of an unstable clinical condition, psychiatric condition, or vital signs/physical/laboratory/ abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of study results.
  • Participant had a major surgery within 8 weeks prior to baseline (Day 1 or has a major surgery planned during the study.
  • Participant has a history of Class III or IV congestive heart failure as defined by Criteria.
  • Participant has an estimated of \< 40 mL/min based on the Cockcroft-Gault equation or a history of renal failure.
  • Participant was hospitalized in the 3 months prior to screening for asthma, has ever required intubation for treatment of asthma, currently require oral corticosteroids for the treatment of asthma, or has required more than one short-term (≤ 2 weeks) course of oral corticosteroids for asthma within 6 months prior to baseline (Day 1).
  • Participant has a history of cancer or lymphoproliferative disease within 5 years prior to baseline (Day 1). Participants with successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix are not to be excluded.
  • Participant has a history of fever, inflammation, or systemic signs of illness suggestive of systemic or invasive infection within 4 weeks prior to baseline (Day 1).
  • Participant has an active bacterial, viral, fungal, mycobacterial infection, or other infection (including TB or atypical mycobacterial disease), or any major episode of infection that required hospitalization or treatment with intravenous antibiotics within 12 weeks prior to baseline (Day 1), or oral antibiotics within 4 weeks prior to baseline (Day 1).
  • Participant has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection, recurrent urinary tract infection, fungal infection (with the exception of superficial fungal infection of the nailbed), or infected skin wounds or ulcers.
  • Participant has a history of an infected joint prosthesis or has received antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced.
  • Participant has active herpes infection, including herpes simplex 1 and 2 and herpes zoster within 8 weeks prior to Day 1.
  • Participant has a history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the Participant's immune status (eg, history of splenectomy, primary immunodeficiency).
  • Participant has positive results for surface antigens (HBsAg), antibodies to hepatitis B core antigens (anti-HBc), virus (HCV), or (HIV). Samples testing positive for HCV antibodies will require polymerase chain reaction (PCR) qualitative testing for HCV RNA.
  • Participant has clinical or laboratory evidence of active or latent TB infection at screening as assessed by QuantiFERON-TB Gold (or a purified protein derivative [PPD] skin test or equivalent, or both if required per local guidelines) and chest X-ray. The PPD skin test should be utilized only when a QuantiFERON-TB Gold Test is not possible for any reason (unless local guidelines require both tests). Chest X-ray may be taken at screening or completed within 3 months prior to the screening visit, with documentation showing no evidence of infection or as read by a qualified physician.
  • Participant has a known or suspected allergy to NDI-034858 or any component of the investigational product, or any other significant drug allergy (such as anaphylaxis or hepatotoxicity).
  • Participant has a known history of clinically significant drug or alcohol abuse in the last year prior to baseline (Day 1).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
305 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo capsules, orally, QD for 12 weeks.

    Other: Placebo

  • Experimental
    NDI-034858 Low Dose

    Participants received NDI-034858 low dose, capsules, orally, QD for 12 weeks.

    Drug: NDI-034858

  • Experimental
    NDI-034858 Medium Dose

    Participants received NDI-034858 medium dose, capsules, orally, QD for 12 weeks.

    Drug: NDI-034858

  • Experimental
    NDI-034858 High Dose

    Participants received NDI-034858 high dose, capsules, orally, QD for 12 weeks.

    Drug: NDI-034858

Interventions

  • NDI-034858 oral capsule

    Also known as: TAK-279

  • OtherPlacebo

    NDI-034858-matching oral placebo capsule

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved at Least an American College of Rheumatology 20 (ACR20) Response at Week 12

    ACR20 is composite measure defined as improvement of 20 percent(%) from baseline in both number of tender (68) \& number of swollen (66) joints \& a 20% improvement in at least 3 of following 5 criteria: patient global assessment of psoriatic arthritis (PGA-PsA) \[visual analog scale (VAS) where, 0=very good, no symptoms \& 100=very poor, severe symptoms\], physician global assessment of psoriatic arthritis (PhGA-PsA) \[(VAS) where 0=no disease activity \& 100=maximum disease activity\], patient global assessment of psoriatic arthritis pain (PGAAP) \[(VAS) where 0=no pain \& 100=most severe pain\], disability history questionnaire i.e., Health Assessment Questionnaire-Disability Index \[HAQ-DI\] (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip \& activities, 0=without difficulty to 3=unable to do) \& acute phase reactant like high sensitivity C-reactive protein \[hsCRP\]). Percentages are rounded off to the nearest decimal.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Who Achieved at Least an ACR-50 Response at Week 12

    The ACR-50 is a composite measure defined as improvement of 50% from baseline in both the number of tender (68) and number of swollen (66) joints, and a 50% improvement in at least three of the following five criteria: PGA-PsA (VAS where, 0 is 'very good, no symptoms' and 100 is 'very poor, severe symptoms'), PhGA-PsA \[(VAS) where 0=no disease activity and 100=maximum disease activity\], PGAAP \[(VAS) where 0=no pain \& 100=most severe pain\], disability history questionnaire (i.e., HAQ-DI) \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do\] and an acute phase reactant \[i.e., erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)\]. Percentages are rounded off to the nearest decimal.

    Time frame: Week 12

  2. Percentage of Participants Who Achieved at Least an ACR-70 Response at Week 12

    The ACR-70 is a composite measure defined as improvement of 70% from baseline in both the number of tender (68) and number of swollen (66) joints, and a 70% improvement in at least three of the following five criteria: PGA-PsA (VAS where, 0 is 'very good, no symptoms' and 100 is 'very poor, severe symptoms'), PhGA-PsA \[(VAS) where 0=no disease activity and 100=maximum disease activity\], PGAAP \[(VAS) where 0=no pain \& 100=most severe pain\], disability history questionnaire (i.e., HAQ-DI) \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do\] and an acute phase reactant (i.e., ESR or CRP). Percentages are rounded off to the nearest decimal.

    Time frame: Week 12

  3. Change From Baseline in Tender Joint Count (TJC) at Week 12

    The TJC 68 is a total score of points assigned for the presence of tenderness in the 68 joints in the upper body and upper/lower extremity. The response to tenderness for each joint was evaluated using the following scale: 'Present' was assigned a score of 1 whereas, 'Absent', 'Not Done', 'Not Applicable', or joints with missing response were assigned a score of 0. The sum of all tender joints was derived. The overall tender joint count ranged from 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 12

  4. Change From Baseline in Swollen Joint Count (SJC) at Week 12

    The SJC 66 (TJC 68 joint assessment minus hip joints, which cannot be assessed for swelling) is a total score of points assigned for presence of swelling in the 66 joints in the upper body and upper/lower extremity. The response to swelling for each joint was evaluated using the following scale: 'Present' was assigned a score of 1 whereas, 'Absent', 'Not Done', 'Not Applicable', or joints with missing response were assigned a score of 0. The sum of all swollen joints was derived. The overall swollen joint count ranged from 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 12

  5. Change From Baseline in PGA-PsA at Week 12

    Participants assessed their overall disease status based on symptoms of psoriasis and psoriatic arthritis at the time of the visit using the PGA-PsA VAS of 100 millimeters (mm) which ranges from 0 (very good, no symptoms) to 100 (very poor, severe symptoms). A negative change from Baseline indicates improvement in symptoms.

    Time frame: Baseline, Week 12

  6. Change From Baseline in PGAAP at Week 12

    Participants assessed their overall psoriatic arthritis-related pain at the time of the visit using the PGAAP VAS of 100 mm which ranges from 0 (no pain) to 100 (most severe pain). A negative change from Baseline indicates improvement in pain.

    Time frame: Baseline, Week 12

  7. Change From Baseline in PhGA-PsA at Week 12

    The participants' overall disease status was assessed, taking into account signs, symptoms, and function, of all components of joint and skin affected at the time of the visit and this overall status was rated by the investigator using the PhGA-PsA VAS of 100 mm where 0 is 'very good, asymptomatic, and no limitation of normal activities' and 100 is 'very poor, very severe symptoms which are intolerable, and inability to carry out all normal activities'. A negative change from Baseline indicates improvement in symptoms.

    Time frame: Baseline, Week 12

  8. Change From Baseline in HAQ-DI Total Score at Week 12

    The HAQ-DI consists of 20 questions referring to eight domains consisting of dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored from 0 (without any difficulty) to 3 (unable to do). The worst score within each domain will be used as the domain score (i.e., if the score for one question is 1 and 2 for the other, then the worst score for the domain is 2). The HAQ-DI total score is calculated by dividing the sum of the domain scores by the number of non-missing domains. The total score indicates the patient's self-assessed level of functional ability and higher scores indicate worse functional ability. The HAQ-DI total score ranges from 0 to 3. A higher score indicates worse function and greater disability. A negative change from Baseline indicates improved function.

    Time frame: Baseline, Week 12

  9. Change From Baseline in Dactylitis Count (DC) at Week 12

    Tender score (0 = no tenderness, 1 = tender, 2 = tender and wince, 3 = tender and withdraw) is collected for Dactylitis Assessments on the Dactylitis Score Sheet that is used for calculation of total score. DC equals the number of tender fingers and toes (tender score \>0). For participants with dactylitis status absent for all the fingers and toes, the DC is set as 0. The total score range of DC is from 0 to 60, higher scores indicate greater presence of dactylitis. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 12

  10. Change From Baseline in Leeds Enthesitis Index (LEI) at Week 12

    Enthesitis is assessed using LEI. The enthesitis examination by LEI evaluates the presence or absence of pain by applying local pressure on 6 anatomical sites: medial femoral condyle (left and right), lateral epicondyle (left and right), and the achilles tendon insertion (left and right). Enthesitis at each site is scored as 0 (enthesitis absent) and 1 (enthesitis present). LEI is derived as the sum of the enthesitis score over the 6 sites, divided by the number of sites with non-missing score. The total score ranges from 0 to 6, higher scores indicate greater degree of enthesitis. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 12

  11. Percentage of Participants With Minimal Disease Activity (MDA) Response at Week 12

    MDA is a measure to indicate a state of minimal disease activity, and is a composite score of 7 domains. A participant is considered as having achieved the MDA if the participant fulfills at least 5 of the following 7 criteria: TJC 68 ≤1; SJC 66 ≤1; Psoriasis area and severity index (PASI) score ≤1 \[The total score ranges from 0 (no disease) to 72 (maximal disease)\] or body surface area (BSA) ≤3%; PGAAP ≤15 \[using VAS on a scale of 0 (no pain) to 100 (serious pain)\]; PGA-PsA ≤20 \[using VAS on a scale of 0 (very well) to 100 (very poor)\]; HAQ-DI score ≤0.5; LEI score ≤1. Percentages are rounded off to the nearest decimal.

    Time frame: Week 12

  12. Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Week 12

    The DAPSA score is a composite score and was calculated using: TJC68, SJC66, PGA-PsA, PGAAP, and hsCRP level (milligram per deciliter \[mg/dL\]). DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. The DAPSA score has a lower bound of 0 and has no upper bound. A higher DAPSA score indicated more active disease activity. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 12

  13. Percentage of Participants Who Achieved PASI-75 Response at Week 12

    PASI-75 is assessed in participants with psoriasis involvement for ≥ 3% of the BSA at Baseline and assesses the extent of involvement and severity of psoriasis. To calculate the PASI, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI-75, the improvement threshold from baseline in PASI score is 75%. A higher score indicates more severe disease. Percentages are rounded off to the nearest decimal.

    Time frame: Week 12

  14. Percentage of Participants Who Achieved a Physician Global Assessment of Psoriasis (PhGA-PsO) of 0 or 1 and at Least a 2-point Improvement at Week 12

    PhGA-PsO responder is defined as participants 1) who had PhGA-PsO score of 0 or 1 at any given post-baseline visit; and 2) who had at least 2-point improvement from baseline. The PhGA-PsO is measured using a 0 to 4 scale with a 0 meaning clear or a 4 meaning severe. The proportion of participants achieving PhGA-PsO response at Week 12 was calculated and analyzed for participants with a score of at least 2 at baseline. Percentages are rounded off to the nearest decimal.

    Time frame: Week 12

  15. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

    Adverse Event(AE)=medical occurrence that does not necessarily have a causal relationship with this drug also including clinically meaningful findings in laboratory safety tests,vital signs,weight,and electrocardiogram(ECG).TEAEs=AEs occurring at time of or post study drug dosing until study end.SAE=any medical occurrence at any dose that resulted in death,was life-threatening,required inpatient hospitalization/prolongation of existing hospitalization,resulted in persistent or significant disability/incapacity,was a congenital abnormality/birth defect,an important medical event.AESIs included Common Terminology Criteria for Adverse Events(CTCAE)Grade≥2 cytopenia,CTCAE Grade≥3 elevation of creatine phosphokinase(CPK)\[clinically significant or not\]defined as CPK\>5xupper limit of normal(ULN),infections,adverse events of abnormal liver function tests,adverse events of renal dysfunction,major adverse cardiovascular events,thromboembolic events,gastrointestinal perforation,and malignancies.

    Time frame: From first dose of study drug up to end of study (up to Week 16)

  16. Plasma Concentration of NDI-034858

    Plasma concentration of NDI-034858 was measured in participants who received low, medium, or high doses of NDI-034858.

    Time frame: Pre-dose, 1 hour post-dose on Day 1 and Week 4, 4 hours post-dose at Week 4, Pre-dose at Week 8, and anytime at Week 12

07

Results

Posted May 31, 2024

Participant flow

Participants took part in the study at 45 investigative sites in the United States (US), Germany, Poland, and the Czech Republic from 6 January 2022 to 2 June 2023.

Participant flow — Overall Study
MilestonePlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Started75767876
Completed66666560
Not completed9101316
Withdrew: Adverse event1035
Withdrew: Lost to follow-up1120
Withdrew: Withdrawal by subject6868
Withdrew: Coronavirus disease 2019 (covid-19)0010
Withdrew: Randomized without dosing due to ineligibility0002
Withdrew: Reason not specified1111

Outcome measures

PrimaryPercentage of Participants Who Achieved at Least an American College of Rheumatology 20 (ACR20) Response at Week 12

ACR20 is composite measure defined as improvement of 20 percent(%) from baseline in both number of tender (68) \& number of swollen (66) joints \& a 20% improvement in at least 3 of following 5 criteria: patient global assessment of psoriatic arthritis (PGA-PsA) \[visual analog scale (VAS) where, 0=very good, no symptoms \& 100=very poor, severe symptoms\], physician global assessment of psoriatic arthritis (PhGA-PsA) \[(VAS) where 0=no disease activity \& 100=maximum disease activity\], patient global assessment of psoriatic arthritis pain (PGAAP) \[(VAS) where 0=no pain \& 100=most severe pain\], disability history questionnaire i.e., Health Assessment Questionnaire-Disability Index \[HAQ-DI\] (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip \& activities, 0=without difficulty to 3=unable to do) \& acute phase reactant like high sensitivity C-reactive protein \[hsCRP\]). Percentages are rounded off to the nearest decimal.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved at Least an American College of Rheumatology 20 (ACR20) Response at Week 12
percentage of participantsPlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Percentage of Participants Who Achieved at Least an American College of Rheumatology 20 (ACR20) Response at Week 1229.2 (18.7 to 39.7)35.2 (24.1 to 46.3)53.3 (42.0 to 64.6)54.2 (42.7 to 65.7)
Statistical analysis
  • Placebo vs NDI-034858 Low Dose · Cochran-Mantel-Haenszel · p = =0.446 · Risk difference (rd): 5.9 · 95% CI -9.3 to 21.1Mantel-Haenszel (MH) risk difference was summarized along with the 2-sided 95% confidence interval (CI) using MH stratum weights and the Sato variance estimator.
  • Placebo vs NDI-034858 Medium Dose · Cochran-Mantel-Haenszel · p = =0.002 · Risk difference (rd): 24.1 · 95% CI 8.6 to 39.6MH risk difference was summarized along with the 2-sided 95% CI using MH stratum weights and the Sato variance estimator.
  • Placebo vs NDI-034858 High Dose · Cochran-Mantel-Haenszel · p = =0.002 · Risk difference (rd): 24.5 · 95% CI 9.0 to 39.9MH risk difference was summarized along with the 2-sided 95% CI using MH stratum weights and the Sato variance estimator.
SecondaryPercentage of Participants Who Achieved at Least an ACR-50 Response at Week 12

The ACR-50 is a composite measure defined as improvement of 50% from baseline in both the number of tender (68) and number of swollen (66) joints, and a 50% improvement in at least three of the following five criteria: PGA-PsA (VAS where, 0 is 'very good, no symptoms' and 100 is 'very poor, severe symptoms'), PhGA-PsA \[(VAS) where 0=no disease activity and 100=maximum disease activity\], PGAAP \[(VAS) where 0=no pain \& 100=most severe pain\], disability history questionnaire (i.e., HAQ-DI) \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do\] and an acute phase reactant \[i.e., erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)\]. Percentages are rounded off to the nearest decimal.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved at Least an ACR-50 Response at Week 12
percentage of participantsPlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Percentage of Participants Who Achieved at Least an ACR-50 Response at Week 129.7 (2.9 to 16.6)15.5 (7.1 to 23.9)26.7 (16.7 to 36.7)26.4 (16.2 to 36.6)
Statistical analysis
  • Placebo vs NDI-034858 Low Dose · Cochran-Mantel-Haenszel · p = =0.312 · Risk difference (rd): 5.7 · 95% CI -5.3 to 16.6MH risk difference was summarized along with the 2-sided 95% CI using MH stratum weights and the Sato variance estimator.
  • Placebo vs NDI-034858 Medium Dose · Cochran-Mantel-Haenszel · p = =0.005 · Risk difference (rd): 17.0 · 95% CI 5.0 to 29.1MH risk difference was summarized along with the 2-sided 95% CI using MH stratum weights and the Sato variance estimator.
  • Placebo vs NDI-034858 High Dose · Cochran-Mantel-Haenszel · p = =0.009 · Risk difference (rd): 16.4 · 95% CI 4.2 to 28.6MH risk difference was summarized along with the 2-sided 95% CI using MH stratum weights and the Sato variance estimator.
SecondaryPercentage of Participants Who Achieved at Least an ACR-70 Response at Week 12

The ACR-70 is a composite measure defined as improvement of 70% from baseline in both the number of tender (68) and number of swollen (66) joints, and a 70% improvement in at least three of the following five criteria: PGA-PsA (VAS where, 0 is 'very good, no symptoms' and 100 is 'very poor, severe symptoms'), PhGA-PsA \[(VAS) where 0=no disease activity and 100=maximum disease activity\], PGAAP \[(VAS) where 0=no pain \& 100=most severe pain\], disability history questionnaire (i.e., HAQ-DI) \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do\] and an acute phase reactant (i.e., ESR or CRP). Percentages are rounded off to the nearest decimal.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved at Least an ACR-70 Response at Week 12
percentage of participantsPlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Percentage of Participants Who Achieved at Least an ACR-70 Response at Week 125.6 (1.5 to 13.6)8.5 (2.0 to 14.9)14.7 (6.7 to 22.7)13.9 (5.9 to 21.9)
Statistical analysis
  • Placebo vs NDI-034858 Low Dose · Fisher Exact · p = =0.532 · Risk difference (rd): 2.9 · 95% CI -6.6 to 12.7Comparisons of ACR70 responder rates at Week 12 were made independently between each dose group and the placebo group using Fischer's exact Method.
  • Placebo vs NDI-034858 Medium Dose · Fisher Exact · p = =0.101 · Risk difference (rd): 9.1 · 95% CI -1.0 to 20.1Comparisons of ACR70 responder rates at Week 12 were made independently between each dose group and the placebo group using Fischer's exact Method.
  • Placebo vs NDI-034858 High Dose · Fisher Exact · p = =0.158 · Risk difference (rd): 8.3 · 95% CI -1.7 to 19.4Comparisons of ACR70 responder rates at Week 12 were made independently between each dose group and the placebo group using Fischer's exact Method.
SecondaryChange From Baseline in Tender Joint Count (TJC) at Week 12

The TJC 68 is a total score of points assigned for the presence of tenderness in the 68 joints in the upper body and upper/lower extremity. The response to tenderness for each joint was evaluated using the following scale: 'Present' was assigned a score of 1 whereas, 'Absent', 'Not Done', 'Not Applicable', or joints with missing response were assigned a score of 0. The sum of all tender joints was derived. The overall tender joint count ranged from 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · tender joints
Change From Baseline in Tender Joint Count (TJC) at Week 12
tender jointsPlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Change From Baseline in Tender Joint Count (TJC) at Week 12-5.9 ± 1.12-7.6 ± 1.12-8.9 ± 1.12-8.3 ± 1.15
Statistical analysis
  • Placebo vs NDI-034858 Low Dose · Mixed Model Repeated Measure (MMRM) · p = =0.268 · Treatment difference: -1.7 · 95% CI -4.8 to 1.3Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 Medium Dose · MMRM · p = =0.051 · Treatment difference: -3.0 · 95% CI -6.1 to 0.0Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 High Dose · MMRM · p = =0.112 · Treatment difference: -2.5 · 95% CI -5.6 to 0.6Point estimate and 95% CI were obtained from a MMRM model.
SecondaryChange From Baseline in Swollen Joint Count (SJC) at Week 12

The SJC 66 (TJC 68 joint assessment minus hip joints, which cannot be assessed for swelling) is a total score of points assigned for presence of swelling in the 66 joints in the upper body and upper/lower extremity. The response to swelling for each joint was evaluated using the following scale: 'Present' was assigned a score of 1 whereas, 'Absent', 'Not Done', 'Not Applicable', or joints with missing response were assigned a score of 0. The sum of all swollen joints was derived. The overall swollen joint count ranged from 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · swollen joints
Change From Baseline in Swollen Joint Count (SJC) at Week 12
swollen jointsPlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Change From Baseline in Swollen Joint Count (SJC) at Week 12-3.9 ± 0.57-4.8 ± 0.58-5.0 ± 0.58-5.0 ± 0.59
Statistical analysis
  • Placebo vs NDI-034858 Low Dose · MMRM · p = =0.280 · Treatment difference: -0.9 · 95% CI -2.4 to 0.7Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 Medium Dose · MMRM · p = =0.177 · Treatment difference: -1.1 · 95% CI -2.6 to 0.5Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 High Dose · MMRM · p = =0.196 · Treatment difference: -1.0 · 95% CI -2.6 to 0.5Point estimate and 95% CI were obtained from a MMRM model.
SecondaryChange From Baseline in PGA-PsA at Week 12

Participants assessed their overall disease status based on symptoms of psoriasis and psoriatic arthritis at the time of the visit using the PGA-PsA VAS of 100 millimeters (mm) which ranges from 0 (very good, no symptoms) to 100 (very poor, severe symptoms). A negative change from Baseline indicates improvement in symptoms.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · mm
Change From Baseline in PGA-PsA at Week 12
mmPlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Change From Baseline in PGA-PsA at Week 12-11.1 ± 2.85-12.9 ± 2.84-20.2 ± 2.85-19.8 ± 2.92
Statistical analysis
  • Placebo vs NDI-034858 Low Dose · MMRM · p = =0.637 · Treatment difference: -1.9 · 95% CI -9.6 to 5.9Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 Medium Dose · MMRM · p = =0.021 · Treatment difference: -9.2 · 95% CI -17.0 to -1.4Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 High Dose · MMRM · p = =0.030 · Treatment difference: -8.7 · 95% CI -16.5 to -0.9Point estimate and 95% CI were obtained from a MMRM model.
SecondaryChange From Baseline in PGAAP at Week 12

Participants assessed their overall psoriatic arthritis-related pain at the time of the visit using the PGAAP VAS of 100 mm which ranges from 0 (no pain) to 100 (most severe pain). A negative change from Baseline indicates improvement in pain.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · mm
Change From Baseline in PGAAP at Week 12
mmPlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Change From Baseline in PGAAP at Week 12-12.1 ± 2.75-13.0 ± 2.74-18.8 ± 2.75-18.4 ± 2.82
Statistical analysis
  • Placebo vs NDI-034858 Low Dose · MMRM · p = =0.812 · Treatment difference: -0.9 · 95% CI -8.4 to 6.6Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 Medium Dose · MMRM · p = =0.079 · Treatment difference: -6.7 · 95% CI -14.2 to 0.8Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 High Dose · MMRM · p = =0.102 · Treatment difference: -6.3 · 95% CI -13.9 to 1.3Point estimate and 95% CI were obtained from a MMRM model.
SecondaryChange From Baseline in PhGA-PsA at Week 12

The participants' overall disease status was assessed, taking into account signs, symptoms, and function, of all components of joint and skin affected at the time of the visit and this overall status was rated by the investigator using the PhGA-PsA VAS of 100 mm where 0 is 'very good, asymptomatic, and no limitation of normal activities' and 100 is 'very poor, very severe symptoms which are intolerable, and inability to carry out all normal activities'. A negative change from Baseline indicates improvement in symptoms.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · mm
Change From Baseline in PhGA-PsA at Week 12
mmPlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Change From Baseline in PhGA-PsA at Week 12-20.7 ± 2.66-29.6 ± 2.65-31.3 ± 2.65-31.6 ± 2.73
Statistical analysis
  • Placebo vs NDI-034858 Low Dose · MMRM · p = =0.016 · Treatment difference: -8.9 · 95% CI -16.2 to -1.7Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 Medium Dose · MMRM · p = =0.004 · Treatment difference: -10.6 · 95% CI -17.8 to -3.4Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 High Dose · MMRM · p = =0.003 · Treatment difference: -10.9 · 95% CI -18.2 to -3.6Point estimate and 95% CI were obtained from a MMRM model.
SecondaryChange From Baseline in HAQ-DI Total Score at Week 12

The HAQ-DI consists of 20 questions referring to eight domains consisting of dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored from 0 (without any difficulty) to 3 (unable to do). The worst score within each domain will be used as the domain score (i.e., if the score for one question is 1 and 2 for the other, then the worst score for the domain is 2). The HAQ-DI total score is calculated by dividing the sum of the domain scores by the number of non-missing domains. The total score indicates the patient's self-assessed level of functional ability and higher scores indicate worse functional ability. The HAQ-DI total score ranges from 0 to 3. A higher score indicates worse function and greater disability. A negative change from Baseline indicates improved function.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in HAQ-DI Total Score at Week 12
score on a scalePlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Change From Baseline in HAQ-DI Total Score at Week 12-0.22 ± 0.053-0.29 ± 0.053-0.32 ± 0.053-0.28 ± 0.055
Statistical analysis
  • Placebo vs NDI-034858 Low Dose · MMRM · p = =0.357 · Treatment difference: -0.07 · 95% CI -0.21 to 0.08Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 Medium Dose · MMRM · p = =0.195 · Treatment difference: -0.10 · 95% CI -0.24 to 0.05Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 High Dose · MMRM · p = =0.467 · Treatment difference: -0.05 · 95% CI -0.20 to 0.09Point estimate and 95% CI were obtained from a MMRM model.
SecondaryChange From Baseline in Dactylitis Count (DC) at Week 12

Tender score (0 = no tenderness, 1 = tender, 2 = tender and wince, 3 = tender and withdraw) is collected for Dactylitis Assessments on the Dactylitis Score Sheet that is used for calculation of total score. DC equals the number of tender fingers and toes (tender score \>0). For participants with dactylitis status absent for all the fingers and toes, the DC is set as 0. The total score range of DC is from 0 to 60, higher scores indicate greater presence of dactylitis. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · dactylitis count
Change From Baseline in Dactylitis Count (DC) at Week 12
dactylitis countPlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Change From Baseline in Dactylitis Count (DC) at Week 12-2.1 ± 0.39-0.8 ± 0.41-2.0 ± 0.47-1.9 ± 0.41
Statistical analysis
  • Placebo vs NDI-034858 Low Dose · MMRM · p = =0.031 · Treatment difference: 1.3 · 95% CI 0.1 to 2.4Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 Medium Dose · MMRM · p = =0.860 · Treatment difference: 0.1 · 95% CI -1.1 to 1.3Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 High Dose · MMRM · p = =0.758 · Treatment difference: 0.2 · 95% CI -0.9 to 1.3Point estimate and 95% CI were obtained from a MMRM model.
SecondaryChange From Baseline in Leeds Enthesitis Index (LEI) at Week 12

Enthesitis is assessed using LEI. The enthesitis examination by LEI evaluates the presence or absence of pain by applying local pressure on 6 anatomical sites: medial femoral condyle (left and right), lateral epicondyle (left and right), and the achilles tendon insertion (left and right). Enthesitis at each site is scored as 0 (enthesitis absent) and 1 (enthesitis present). LEI is derived as the sum of the enthesitis score over the 6 sites, divided by the number of sites with non-missing score. The total score ranges from 0 to 6, higher scores indicate greater degree of enthesitis. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Leeds Enthesitis Index (LEI) at Week 12
score on a scalePlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Change From Baseline in Leeds Enthesitis Index (LEI) at Week 12-0.9 ± 0.24-1.4 ± 0.24-1.6 ± 0.24-1.0 ± 0.25
Statistical analysis
  • Placebo vs NDI-034858 Low Dose · MMRM · p = =0.131 · Treatment difference: -0.5 · 95% CI -1.2 to 0.2Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 Medium Dose · MMRM · p = =0.043 · Treatment difference: -0.7 · 95% CI -1.3 to 0.0Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 High Dose · MMRM · p = =0.687 · Treatment difference: -0.1 · 95% CI -0.8 to 0.5Point estimate and 95% CI were obtained from a MMRM model.
SecondaryPercentage of Participants With Minimal Disease Activity (MDA) Response at Week 12

MDA is a measure to indicate a state of minimal disease activity, and is a composite score of 7 domains. A participant is considered as having achieved the MDA if the participant fulfills at least 5 of the following 7 criteria: TJC 68 ≤1; SJC 66 ≤1; Psoriasis area and severity index (PASI) score ≤1 \[The total score ranges from 0 (no disease) to 72 (maximal disease)\] or body surface area (BSA) ≤3%; PGAAP ≤15 \[using VAS on a scale of 0 (no pain) to 100 (serious pain)\]; PGA-PsA ≤20 \[using VAS on a scale of 0 (very well) to 100 (very poor)\]; HAQ-DI score ≤0.5; LEI score ≤1. Percentages are rounded off to the nearest decimal.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Minimal Disease Activity (MDA) Response at Week 12
percentage of participantsPlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Percentage of Participants With Minimal Disease Activity (MDA) Response at Week 1212.5 (4.9 to 20.1)18.3 (9.3 to 27.3)28.0 (17.8 to 38.2)29.2 (18.7 to 39.7)
Statistical analysis
  • Placebo vs NDI-034858 Low Dose · Cochran-Mantel-Haenszel · p = =0.349 · Risk difference (rd): 5.6 · 95% CI -6.1 to 17.4MH risk difference was summarized along with the 2-sided 95% CI using MH stratum weights and the Sato variance estimator.
  • Placebo vs NDI-034858 Medium Dose · Cochran-Mantel-Haenszel · p = =0.017 · Risk difference (rd): 15.5 · 95% CI 2.8 to 28.3MH risk difference was summarized along with the 2-sided 95% CI using MH stratum weights and the Sato variance estimator.
  • Placebo vs NDI-034858 High Dose · Cochran-Mantel-Haenszel · p = =0.014 · Risk difference (rd): 16.3 · 95% CI 3.3 to 29.3MH risk difference was summarized along with the 2-sided 95% CI using MH stratum weights and the Sato variance estimator.
SecondaryChange From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Week 12

The DAPSA score is a composite score and was calculated using: TJC68, SJC66, PGA-PsA, PGAAP, and hsCRP level (milligram per deciliter \[mg/dL\]). DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. The DAPSA score has a lower bound of 0 and has no upper bound. A higher DAPSA score indicated more active disease activity. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Week 12
score on a scalePlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Week 12-11.56 ± 1.948-15.30 ± 1.946-17.99 ± 1.943-16.79 ± 1.989
Statistical analysis
  • Placebo vs NDI-034858 Low Dose · MMRM · p = =0.167 · Treatment difference: -3.73 · 95% CI -9.04 to 1.57Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 Medium Dose · MMRM · p = =0.018 · Treatment difference: -6.43 · 95% CI -11.73 to -1.13Point estimate and 95% CI were obtained from a MMRM model.
  • Placebo vs NDI-034858 High Dose · MMRM · p = =0.056 · Treatment difference: -5.23 · 95% CI -10.59 to 0.13Point estimate and 95% CI were obtained from a MMRM model.
SecondaryPercentage of Participants Who Achieved PASI-75 Response at Week 12

PASI-75 is assessed in participants with psoriasis involvement for ≥ 3% of the BSA at Baseline and assesses the extent of involvement and severity of psoriasis. To calculate the PASI, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI-75, the improvement threshold from baseline in PASI score is 75%. A higher score indicates more severe disease. Percentages are rounded off to the nearest decimal.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI-75 Response at Week 12
percentage of participantsPlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Percentage of Participants Who Achieved PASI-75 Response at Week 1215.4 (4.1 to 26.7)25.6 (11.9 to 39.3)28.3 (15.2 to 41.3)45.7 (31.3 to 60.0)
Statistical analysis
  • Placebo vs NDI-034858 Low Dose · Cochran-Mantel-Haenszel · p = =0.186 · Risk difference (rd): 11.9 · 95% CI -5.7 to 29.4MH risk difference was summarized along with the 2-sided 95% CI using MH stratum weights and the Sato variance estimator.
  • Placebo vs NDI-034858 Medium Dose · Cochran-Mantel-Haenszel · p = =0.101 · Risk difference (rd): 14.6 · 95% CI -2.8 to 32.1MH risk difference was summarized along with the 2-sided 95% CI using MH stratum weights and the Sato variance estimator.
  • Placebo vs NDI-034858 High Dose · Cochran-Mantel-Haenszel · p = =0.002 · Risk difference (rd): 29.0 · 95% CI 10.5 to 47.6MH risk difference was summarized along with the 2-sided 95% CI using MH stratum weights and the Sato variance estimator.
SecondaryPercentage of Participants Who Achieved a Physician Global Assessment of Psoriasis (PhGA-PsO) of 0 or 1 and at Least a 2-point Improvement at Week 12

PhGA-PsO responder is defined as participants 1) who had PhGA-PsO score of 0 or 1 at any given post-baseline visit; and 2) who had at least 2-point improvement from baseline. The PhGA-PsO is measured using a 0 to 4 scale with a 0 meaning clear or a 4 meaning severe. The proportion of participants achieving PhGA-PsO response at Week 12 was calculated and analyzed for participants with a score of at least 2 at baseline. Percentages are rounded off to the nearest decimal.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Physician Global Assessment of Psoriasis (PhGA-PsO) of 0 or 1 and at Least a 2-point Improvement at Week 12
percentage of participantsPlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Percentage of Participants Who Achieved a Physician Global Assessment of Psoriasis (PhGA-PsO) of 0 or 1 and at Least a 2-point Improvement at Week 1215.8 (6.3 to 25.3)20.4 (9.6 to 31.1)20.6 (10.6 to 30.6)32.8 (20.7 to 44.8)
Statistical analysis
  • Placebo vs NDI-034858 Low Dose · Cochran-Mantel-Haenszel · p = =0.540 · Risk difference (rd): 4.5 · 95% CI -10.0 to 19.0MH risk difference was summarized along with the 2-sided 95% CI using MH stratum weights and the Sato variance estimator.
  • Placebo vs NDI-034858 Medium Dose · Cochran-Mantel-Haenszel · p = =0.466 · Risk difference (rd): 5.2 · 95% CI -8.8 to 19.3MH risk difference was summarized along with the 2-sided 95% CI using MH stratum weights and the Sato variance estimator.
  • Placebo vs NDI-034858 High Dose · Cochran-Mantel-Haenszel · p = =0.034 · Risk difference (rd): 16.3 · 95% CI 1.2 to 31.3MH risk difference was summarized along with the 2-sided 95% CI using MH stratum weights and the Sato variance estimator.
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

Adverse Event(AE)=medical occurrence that does not necessarily have a causal relationship with this drug also including clinically meaningful findings in laboratory safety tests,vital signs,weight,and electrocardiogram(ECG).TEAEs=AEs occurring at time of or post study drug dosing until study end.SAE=any medical occurrence at any dose that resulted in death,was life-threatening,required inpatient hospitalization/prolongation of existing hospitalization,resulted in persistent or significant disability/incapacity,was a congenital abnormality/birth defect,an important medical event.AESIs included Common Terminology Criteria for Adverse Events(CTCAE)Grade≥2 cytopenia,CTCAE Grade≥3 elevation of creatine phosphokinase(CPK)\[clinically significant or not\]defined as CPK\>5xupper limit of normal(ULN),infections,adverse events of abnormal liver function tests,adverse events of renal dysfunction,major adverse cardiovascular events,thromboembolic events,gastrointestinal perforation,and malignancies.

Time frame:
From first dose of study drug up to end of study (up to Week 16)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
ParticipantsPlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
TEAEs39424556
SAEs4432
AESIs19332238
SecondaryPlasma Concentration of NDI-034858

Plasma concentration of NDI-034858 was measured in participants who received low, medium, or high doses of NDI-034858.

Time frame:
Pre-dose, 1 hour post-dose on Day 1 and Week 4, 4 hours post-dose at Week 4, Pre-dose at Week 8, and anytime at Week 12
Reported as:
Mean · nanograms per milliliter (ng/mL)
Plasma Concentration of NDI-034858
nanograms per milliliter (ng/mL)NDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Day 1: Pre-dose0.000 ± 0.0000.000 ± 0.0000.000 ± 0.000
Day 1: 1 Hour5.860 ± 7.25125.43 ± 37.2138.32 ± 59.74
Week 4: Pre-dose25.26 ± 17.9582.11 ± 74.46187.5 ± 140.9
Week 4: 1 Hour33.03 ± 24.05112.8 ± 81.19245.3 ± 184.6
Week 4: 4 Hours46.68 ± 25.85149.5 ± 90.56370.1 ± 178.4
Week 8: Pre-dose26.99 ± 21.0078.29 ± 69.37209.4 ± 182.0
Week 12: Any Time24.85 ± 20.5866.17 ± 51.81178.2 ± 149.5

Adverse events

Collected over From first dose of study drug up to end of study (up to Week 16). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/75 (0%)4/72 (5.6%)13/72 (18.1%)
NDI-034858 Low Dose0/76 (0%)4/71 (5.6%)19/71 (26.8%)
NDI-034858 Medium Dose0/78 (0%)3/75 (4%)27/75 (36%)
NDI-034858 High Dose0/76 (0%)2/72 (2.8%)35/72 (48.6%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Atrial fibrillationCardiac disorders0/721/711/750/72
CellulitisInfections and infestations0/721/710/750/72
Coronary artery diseaseCardiac disorders0/721/710/750/72
Respiratory tract infectionInfections and infestations0/721/710/750/72
ArthritisMusculoskeletal and connective tissue disorders1/720/710/750/72
Bell's palsyNervous system disorders0/720/710/751/72
Oesophageal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/720/710/750/72
OsteoarthritisMusculoskeletal and connective tissue disorders1/720/710/750/72
PharyngitisInfections and infestations0/720/710/751/72
Psoriatic arthropathyMusculoskeletal and connective tissue disorders1/720/710/750/72
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High Dose
Upper respiratory tract infectionInfections and infestations2/728/713/757/72
NasopharyngitisInfections and infestations3/726/717/757/72
Aphthous ulcerGastrointestinal disorders0/720/711/756/72
Dermatitis acneiformSkin and subcutaneous tissue disorders0/720/712/756/72
HeadacheNervous system disorders3/722/716/754/72
RashSkin and subcutaneous tissue disorders0/723/716/754/72
Dermatitis allergicSkin and subcutaneous tissue disorders0/721/711/754/72
Psoriatic arthropathyMusculoskeletal and connective tissue disorders4/720/712/751/72
Rash maculo-papularSkin and subcutaneous tissue disorders0/720/712/754/72
Rash papularSkin and subcutaneous tissue disorders0/721/713/754/72

Baseline characteristics

Full Analysis Set included all randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High DoseTotal
Mean49.7 ± 11.8348.3 ± 10.4352.5 ± 12.1549.0 ± 11.5149.9 ± 11.56
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High DoseTotal
Female37404643166
Male35312929124
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High DoseTotal
Hispanic or Latino21429
Not Hispanic or Latino70697170280
Unknown or Not Reported01001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High DoseTotal
White69667169275
Non-white134311
Missing22004
Height
Height(centimeters (cm))PlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High DoseTotal
Mean170.3 ± 10.65170.1 ± 8.67169.0 ± 9.04170.4 ± 9.06169.9 ± 9.35
Weight
Weight(kilograms (kg))PlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High DoseTotal
Mean86.26 ± 25.30786.97 ± 26.61185.85 ± 22.04887.74 ± 20.15286.69 ± 23.529
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per meter square (kg/m^2))PlaceboNDI-034858 Low DoseNDI-034858 Medium DoseNDI-034858 High DoseTotal
Mean29.48 ± 6.86529.78 ± 8.15330.04 ± 7.93730.15 ± 6.61029.87 ± 7.390
08

Study locations

56 sites
  • Nimbus site #XYZ
    Palm Desert, California 92260, United States
  • Nimbus site #XYZ
    Upland, California 91786, United States
  • Nimbus site #XYZ
    Hollywood, Florida 33024, United States
  • Nimbus site #XYZ
    Plantation, Florida 33324, United States
  • Nimbus site #XYZ
    Saint Petersburg, Florida 33705, United States
  • Nimbus site #XYZ
    Tampa, Florida 33613, United States
  • Nimbus site #XYZ
    Tampa, Florida 33614, United States
  • Nimbus site #XYZ
    Winter Park, Florida 32789, United States
  • Nimbus site #XYZ
    Zephyrhills, Florida 33542, United States
  • Nimbus site #XYZ
    Indianapolis, Indiana 46250, United States
  • Nimbus site #XYZ
    West Des Moines, Iowa 50265, United States
  • Nimbus site #XYZ
    Lake Charles, Louisiana 70605, United States
  • Nimbus site #XYZ
    Worcester, Massachusetts 01605, United States
  • Nimbus site #XYZ
    Albuquerque, New Mexico 87102, United States
  • Nimbus site #XYZ
    Charlotte, North Carolina 28210, United States
  • Nimbus site #XYZ
    Duncansville, Pennsylvania 16635, United States
  • Nimbus site #XYZ
    Columbia, South Carolina 29204, United States
  • Nimbus site #XYZ
    Jackson, Tennessee 38305, United States
  • Nimbus site #XYZ
    Baytown, Texas 77521, United States
  • Nimbus site #XYZ
    Corpus Christi, Texas 78404, United States
  • Nimbus site #XYZ
    Houston, Texas 77089, United States
  • Nimbus site #XYZ
    Mesquite, Texas 75150, United States
  • Nimbus site #XYZ
    Beckley, West Virginia 25801, United States
  • Nimbus site #XYZ
    Hlučín, Ostrava-město 748 01, Czechia
  • Nimbus site #XYZ
    Praha, Praha 3 130 00, Czechia
  • Nimbus site #XYZ
    Ostrava, 702 00, Czechia
  • Nimbus site #XYZ
    Pardubice, 530 02, Czechia
  • Nimbus site #XYZ
    Uherské Hradiště, 686 01, Czechia
  • Nimbus site #XYZ
    Zlin, 760 01, Czechia
  • Nimbus site #XYZ
    Cottbus, Brandenburg 03042, Germany
  • Nimbus site #XYZ
    Bonn, Nordrhein-Westfalen 53127, Germany
  • Nimbus site #XYZ
    Cologne, Nordrhein-Westfalen 50937, Germany
  • Nimbus site #XYZ
    Herne, Nordrhein-Westfalen 44649, Germany
  • Nimbus site #XYZ
    Ratingen, Nordrhein-Westfalen 40878, Germany
  • Nimbus site #XYZ
    Berlin, 12161, Germany
  • Nimbus site #XYZ
    Berlin, 14059, Germany
  • Nimbus site #XYZ
    Hamburg, 20095, Germany
  • Nimbus site #XYZ
    Hamburg, 22415, Germany
  • Nimbus site #XYZ
    Lublin, Lubelskie 20-607, Poland
  • Nimbus site #XYZ
    Kraków, Malopolskie 30-033, Poland
  • Nimbus site #XYZ
    Elblag, Warminsko-mazurskie 82-300, Poland
  • Nimbus site #XYZ
    Bialystok, 15-077, Poland
  • Nimbus site #XYZ
    Bydgoszcz, 85-065, Poland
  • Nimbus site #XYZ
    Krakow, 30-363, Poland
  • Nimbus site #XYZ
    Kraków, 30-149, Poland
  • Nimbus site #XYZ
    Nadarzyn, 05-830, Poland
  • Nimbus site #XYZ
    Nowa Sol, 67-100, Poland
  • Nimbus site #XYZ
    Poznan, 60-218, Poland
  • Nimbus site #XYZ
    Poznan, 61-293, Poland
  • Nimbus site #XYZ
    Poznań, 61-397, Poland
  • Nimbus site #XYZ
    Poznań, 61-731, Poland
  • Nimbus site #XYZ
    Sochaczew, 96-500, Poland
  • Nimbus site #XYZ
    Torun, 87-100, Poland
  • Nimbus site #XYZ
    Warszawa, 02-665, Poland
  • Nimbus site #XYZ
    Wroclaw, 50-244, Poland
  • Nimbus site #XYZ
    Wroclaw, 51-318, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in May 2023, 15 months.

Results were first posted in May 2024, 1 year after primary completion.

Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2021
First posted
Dec 10, 2021
StartActual
Jan 6, 2022
Primary completionActual
May 4, 2023
CompletionActual
Jun 2, 2023
Results first posted
May 31, 2024
Last update
May 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05153148
Lead sponsor
Takeda
Collaborators
Nimbus Lakshmi, Inc.
Responsible party
Sponsor
First posted
Dec 10, 2021
Start date
Jan 6, 2022
Primary completion
May 4, 2023
Completion
Jun 2, 2023
Results posted
May 31, 2024
Last update
May 31, 2024

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zasocitinib

Start the discussion